CTL 119

Drug Profile

CTL 119

Alternative Names: Humanised anti-CD19 CAR T cells

Latest Information Update: 21 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Pennsylvania
  • Class CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia

Most Recent Events

  • 04 Jun 2017 Clinical trials in Acute lymphoblastic leukaemia (In Children, Combination therapy, Second-line therapy or greater) in USA (IV), before June 2017
  • 02 Jun 2017 Adverse events and efficacy data from a clinical trial in Acute lymphoblastic leukaemia presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Adverse events and efficacy data from the pilot study in Chronic lymphocytic leukaemia presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top